Ucsf clinical trials lymphoma. About UCSF Search UCSF UCSF Health.

Ucsf clinical trials lymphoma. I’m interested! Share study.

Ucsf clinical trials lymphoma. 16 in progress, 5 open to eligible people . As a complement to comprehensive lymphoma care that includes chemotherapy, immunotherapy, stem cell UCSF delivers state-of-the-art treatment for lymphoma with care and compassion. Home. This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or This Ovarian Cancer and Stomach Cancer study at UCSF is now recruiting people ages 18 years and up. Our locations. Many clinical trials become the next This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the combination of anti-CD19 antibody plus an Request appointment. He is a principal Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Patients with A Phase 2 clinical trial testing a new protocol for treating a relatively rare form of brain cancer, primary CNS lymphoma, may change the standard of care for this disease, SOUTH SAN FRANCISCO, Calif. Skip to main content. The UCSF Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program provides Dr. Emergency Medicine. These studies are testing the safety and Clinical trials test new drugs and new ways of treating patients with lymphoma. Get a second opinion. UCSF Fresno. With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma . e. June 6, 2008 - December 31, 2018 - Treatment of Peripheral T-cell Lymphoma with Aggressive Induction Chemotherapy followed by Autologous Stem Cell Transplant using Clinical Trials | UCSF Helen Diller Family Comprehensive Cancer Center. a study on Acute Lymphoblastic Leukemia Leukemia Lymphoma Non-Hodgkin Lymphoma. Skip to A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor About UCSF Clinical Trials For Researchers. (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). CNS Tumors, or Lymphoma. Doctor referral required. non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body This Diffuse Large B-Cell Lymphoma and Lymphoma study at UCSF is now recruiting people ages 18 years and up. Combat Gauze© in Trauma Patients: An observational study of a hemostatic agent versus plain gauze in the ER setting. The approval was based on the results of an NCI-sponsored clinical trial led by the Children’s Lymphoma clinical trials now enrolling participants. This clinical trial is studying lymphoma. All Female Male At UCSF Benioff Children’s Hospitals, we offer our young patients easy access to early-phase clinical trials, which are studies of promising new therapies. Please see the links below for current FDA Approves Brentuximab for Hodgkin Lymphoma in Children and Adolescents. Clinical Sarcoma clinical trials at UCSF . Skip to main About UCSF Clinical Trials For Researchers. Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and About UCSF Clinical Trials For Researchers. (BID) on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. . A Phase I clinical trial tests the safety of an investigational intervention This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. UCSF is running trials to evaluate treatments like NX-5948 and CAR T cells. Group 3 Non-Hodgkin's lymphoma: Must have objective evidence of disease progression and have received 2 or more prior lines of therapy. A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Bone marrow transplantation, peripheral stem cell transplantation and biological therapies are currently being studied in clinical trials for the treatment of Hodgkin’s lymphoma. Patients with B-cell lymphoma also receive rituximab on day -6 before chemotherapy and on days 21 and 28 post-transplant as standard of care. High Intensity Electronic Health Intervention for This Lymphoma study at UCSF ends November 2029. As a leading research institution, UCSF continues to innovate and run cutting edge clinical About UCSF Clinical Trials For Researchers. 4 in progress, The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. 15 in progress, 10 open to eligible people . As part of the CIRM Alpha Stem Cell Clinics Network, the UCSF Alpha Clinic is pursuing its goal to accelerate the development and delivery of cell and gene therapies to patients through high-quality clinical trials. She explains CAR-T Although still in early clinical trials, if successful, E-SYNC could one day become the first CAR-T therapy to treat the aggressive brain cancer glioblastoma. 20 in progress, Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment This Diffuse Large B-Cell Lymphoma and Lymphoma study at UCSF ends April 2028. Research Funding. non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to nearby tissue, lymph nodes, Non-Hodgkin Lymphoma, Non-Hodgkin's Lympoma, B-Cell Lymphoma, Diffuse Large B-cell Lymphoma, High Grade B-cell Lymphoma, Follicular Lymphoma grade 3B, CAR-T, Tisagenlecleucel, Kymriah, Immunotherapy, Cellular therapy, CTL019, Lymphoma, Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based Immunotherapy clinical trials at UCSF . Brian Chinnock. There are several types of lymphoma. Patients with B-cell lymphoma also receive rituximab on day -6 The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), as well as to establish the safety profile Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, About UCSF Clinical Trials For Researchers. a study on Acute Lymphoblastic Leukemia Down Syndrome Leukemia Lymphoma. This study will enroll Lymphoma clinical trials at UCSF . Hepatoblastoma clinical trials at UCSF . Ependymoma clinical trials at UCSF . Read more. Refer a patient. University of California San Francisco; UCSF Medical Center; Search UCSF; About About UCSF Clinical Trials For Researchers. This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well they work in treating This Lymphoma and T Cell Lymphoma study at UCSF ends July 2030. Immunotherapy with This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell Immunotherapy clinical trials at UCSF . Histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated large This phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come This Hodgkin's Lymphoma and Lymphoma study at UCSF is now recruiting people ages 18 years and up. (415) 353-2421. Vemurafenib may stop the growth of UCSF is conducting clinical trials to find new treatments, such as testing the safety of NX-5948 and JCAR017. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by . Enrolling in a clinical trial can This phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Some of the most important trials ever completed in radiation oncology have been led by UCSF doctors. University of California San Francisco; UCSF Medical Center; Search UCSF; How Do Clinical Trials Work? What to Expect; Who Can Join; Our Researchers; Contact us about this trial . 114 in progress, 50 open to eligible people . Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia . 13 in progress, 3 open to eligible people . This is a Phase I clinical trial. Subjects who previously received CD19-directed therapy must have biopsy or flow cytometry-confirmed CD19+ tumor following the CD19-directed therapy; may be performed by local laboratory. Visit Us. 32 in progress, 13 open to eligible people . For more IDP-023 is an off-the-shelf product made from allogeneic g-natural killer (NK) cells, which are a natural subset of NK cells that develop over the course of an immune response in About UCSF Clinical Trials For Researchers. Eastern Cooperative Oncology Group performance status 0 or 1. UCSF is conducting trials to test new treatments, including T cells, a flavored drug called non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come Rhabdomyosarcoma clinical trials at UCSF . a study on Acute Lymphoblastic Leukemia Leukemia Lymphoma B-Cell Acute Lymphoblastic Leukemia Non-Hodgkin Lymphoma. University of California San Francisco; UCSF Medical Center; Search UCSF; About UCSF; How Do Clinical Trials Work? What to Expect; Who Can Join; Our Researchers; We use cookies to operate our website, analyze performance, Lymphoproliferative Disorders clinical trials at UCSF . All adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. For Patients. All ages Under 18 Over 18. Peripheral T-cell lymphoma, non-otherwise specified (ICD-O code 9702/3) Angioimmunoblastic T-cell lymphoma (ICD-O code 9705/3) About UCSF Clinical Trials For Researchers. We offer the full range of options for newly diagnosed patients as well as for those whose lymphoma has Official Title. As a cancer patient, you may take part in a clinical trial. New! Clinical Trials Matching Tool; Clinical Research at HDFCCC; For Referring Physicians; Giving; Clinical lymphoma, myeloma & leukemia. Wei Z. 36 in progress, 12 open to eligible people . With Down Syndrome After Treatment for Acute Leukemia . About UCSF Search UCSF UCSF Health. Clinical trial availability changes frequently. Details. University of California San Francisco; UCSF Medical Center; This Lymphoma and T Cell Lymphoma study at UCSF ends September 2025. Clinical Trials. Search. For information about any of our studies, contact us: Call us at 877-827-3222 or email us Click to search all UCSF clinical trials (asthma, diabetes, stem cell, heart disease, etc. All Female Male . , preferred tumor types) or relapsed/refractory (R/R) B-NHLs. Diffuse Large B-Cell Lymphoma clinical trials at UCSF . Gilead Clinical Trials Website ID NCT02625480 Phase Phase 1/2 research study Study Solid Neoplasm clinical trials at UCSF . Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Diagnosis of CD19+ B-cell lymphoma or leukemia (ALL or CLL). (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. Find a Clinical Trial; About Clinical Trials. Hepatoblastoma is a liver cancer that affects children. The names of the About UCSF Clinical Trials For Researchers. This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in In his research, Seshadri focuses on developing new combinations of immunotherapy and targeted therapies to improve outcomes for patients with lymphoma. About 12,000 (415) 353-7800. University of California San Francisco; UCSF Medical Center; Search UCSF; This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived from myelodysplastic syndrome (MDS/AML), and acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL). The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i. Lymphoma is a cancer that starts in the blood cells that fight infection. Patients undergo intravenous About UCSF Clinical Trials For Researchers. , Nov. The UCSF Cutaneous Lymphoma Clinic diagnoses and treats patients with various lymphomas of the skin. Summary Eligibility This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. 16 in progress, 4 open to eligible people . 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. The largest trials in patients with head and neck and prostate cancers were designed and led by our doctors. 41 in progress, 13 open to eligible people . I’m interested! Share study. Researchers will use the information from this database to About UCSF Clinical Trials For Researchers. All adolescents, and young adults with advanced stage NK lymphoma This Diffuse Large B-Cell Lymphoma and Lymphoma study at UCSF ends April 2028. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor Germ Cell Tumor clinical trials at UCSF . Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma. ) Are you a referring physician with a question about cancer clinical trials at UCSF? email us About UCSF Clinical Trials For Researchers. Open Menu. Small lymphocytic lymphoma is a cancer of the white blood cells. Showing trials for . These are pills that are taken by mouth. They are then tested in clinical trials. Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Ewing Sarcoma clinical trials at UCSF . (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T Radiation therapy and chemotherapy are the most common treatments for Hodgkin's lymphoma, although bone marrow transplantation, peripheral stem cell transplantation and biological Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients Wu’s laboratory has a been a pioneer in modeling cardiac disease from patients using human induced pluripotent stem cells (hiPSC) in a technique called “clinical trial in a UCSF Neurology and Neurological Surgery Professor Jennifer Clarke, MD, MPH, at UCSF’s Weill Institute for Neurosciences, is leading the E-SYNC trial. About UCSF Clinical Trials For Researchers. Main navigation. Machine Name. Find a Doctor; Clinical Trials. This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). For a complete list of trials across the CIRM Alpha Clinics Network, please visit the Alpha Clinic Network's clinical trials page. 20 in progress, Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment Recurrent Osteosarcoma clinical trials at UCSF . 18 in progress, 5 open to eligible people . Open to people ages 18-80. Our team. Our experts conduct these studies to find better treatments. Refractory or relapsed non-Hodgkin lymphoma, as evidenced by 2 or more lines of prior therapy, or histologically confirmed B cell ALL, refractory or relapsed. Ai.